Population Pharmacokinetic and Exposure-Response Modeling of Patritumab Deruxtecan (HER3-DXd)
Presented at the Indiana CTSI Pharmacometrics Modeling and Simulation Symposium 2025. Dr. Tim Waterhouse explores the complexities of modeling an antibody-drug conjugate (ADC) for targeted cancer treatment, covering pharmacokinetics models with multiple clearance pathways and exposure-response models in a Bayesian framework.